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ABSTRACT 
Multi-parameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-
carbonitriles resulted in the identification of a potent and selective, oral CHK1 preclinical 
development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) 
damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to 
give an integrated assessment of compound selectivity during optimization resulting in a highly 
CHK1 selective, adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector 
directed away from the CHK1 kinase active site was unexpectedly found to drive the selective 
cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-
related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this 
series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic-pharmacodynamic 
(PK-PD) properties gave a compound with low predicted doses and exposures in humans which 
mitigated the residual weak in vitro hERG inhibition. 
 
INTRODUCTION 
The serine-threonine kinase CHK1 is a critical component of the cellular response to DNA 
damage, especially the repair of DNA breaks arising during replication or caused by DNA-
damaging chemotherapies and ionizing radiation.
1
 CHK1 is activated by the upstream kinases 
ataxia telangiectasia and Rad3-related (ATR), and to a lesser extent ataxia telangiectasia mutated 
(ATM).
2
 CHK1 is phosphorylated on residues S317 and S345 by ATR, and undergoes 
autophosphorylation on S296.
3
 The activated enzyme phosphorylates a range of substrates, 
including the cell division cycle 25 (CDC25) family of phosphatases that regulate cell cycle 
 3 
progression, with the result that the cell cycle is halted at checkpoints in Synthesis (S) or Gap 2 
(G2) phase.
4
 At the same time, CHK1 initiates DNA repair by homologous recombination 
through signaling to the repair protein RAD51.
5
 The cell cycle checkpoints controlled by CHK1 
therefore provide an opportunity for repair of the damaged DNA before the replicating cell enters 
mitosis. If the damage is resolved the checkpoint is released and cell growth and division 
recommence, while prolonged activation of the checkpoint leads to senescence or cell death. 
The DNA damage response (DDR) mediated by ATR-CHK1 provides a mechanism for cancer 
cells to resist DNA-damaging anti-cancer therapies and is an attractive point of intervention for 
new treatments.
6
 A strong body of evidence shows that inhibition of CHK1 with small 
molecules, or depletion by ribonucleic acid (RNA) interference, selectively sensitizes tumor cells 
to genotoxic drugs and ionizing radiation.
7
 Normal cells have multiple DNA-damage 
checkpoints, including the important p53-dependent Gap 1 (G1) phase checkpoint. However, 
many cancer cells harbor defects in one or more of these checkpoints, for example due to 
frequent deletion, mutation and loss of function of the tumor suppressor p53, and rely on the S 
and G2 checkpoints mediated by CHK1 to effect repair of DNA damage.
8 
The potential of CHK1 inhibition as a mono-therapy has been demonstrated in tumor cells with 
replication stress. These tumors rely on the CHK1-mediated DDR to repair intrinsically high 
levels of DNA strand breaks, for example arising from increased replication fork stalling in S 
phase, and include cancers driven by v-myc avian myelocytomatosis viral oncogene homolog 
(MYC) and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog 
(MYCN) oncogenes
9,10
, as well as some melanomas and triple-negative breast cancers.
11,12
  
There has been substantial activity in developing CHK1 inhibitors for clinical study in 
combination with various DNA-damaging agents.
7,13
 While the first clinical studies have 
 4 
demonstrated the tolerability of CHK1 inhibition, further progression has often been challenging 
and development of several agents has been halted after early phase clinical trials. Some of the 
first generation inhibitors have low selectivity for CHK1, and were developed as intravenous 
agents. Subsequent to the identification of these compounds, studies showed that maximum 
potentiation of gemcitabine efficacy in preclinical models was associated with exposure to the 
CHK1 inhibitor during a window beginning some 24 h after administration of the genotoxic 
agent.
14,15
 Consequently, an oral compound would offer advantages of ease of administration and 
flexibility of scheduling. In addition, preclinical data on the emerging contexts for CHK1 mono-
therapy suggests that daily dosing may be needed, for which an oral drug would again be 
favored. The oral CHK1 inhibitors GDC-0425 and GDC-0575 have been reported in Phase I 
clinical trials.
16,17
 There remains a clear need for highly selective, oral CHK1 inhibitors from 
different chemical series to advance to clinical studies.  
We previously reported the discovery and optimization of the first published selective, oral 
CHK1 inhibitor (R)-3-((1-(dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1H-
pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (1)
18
 through a scaffold hybridization 
strategy starting from potent, selective but highly metabolized inhibitor (R)-5-((8-
chloroisoquinolin-3-yl)amino)-3-((1-(dimethylamino)propan-2-yl)oxy)pyrazine-2-carbonitrile 
(2) and the less potent but metabolically stable 5-((4-aminopyridin-2-yl)amino)pyrazine-2-
carbonitrile 3 (Figure 1).
19,20
 While effective in preclinical models, compound 1 was suboptimal 
due to low metabolic stability in human hepatocytes, leading to predictions of poor human 
pharmacokinetics (PK) and a requirement for high doses. In parallel with the discovery of 1, we 
pursued the multi-parameter optimization of the 5-((4-aminopyridin-2-yl)amino)pyrazine-2-
carbonitriles based on 3, described herein, resulting in the identification of the potent and highly 
 5 
selective, oral CHK1 clinical candidate, (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-
(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (4; CCT245737).
21
 
 
 
Figure 1. Summary of the evolution of the oral inhibitor tool compound 1
18
 and oral clinical 
development candidate 4.
21 
 
RESULTS AND DISCUSSION 
Assay cascade and target candidate profile 
The desired candidate profile was developed based on our experience with compounds 1 and 2. 
Potent biochemical inhibition of CHK1 (IC50 <10 nM) was required. We measured CHK1 
inhibition using a Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFIA), 
format and also developed a microfluidic assay for CHK1 substrate phosphorylation with a 
larger dynamic range to accurately assess tight-binding compounds. High selectivity for CHK1 
over other kinases was considered essential. In particular, inhibition of the structurally distinct 
DDR protein, checkpoint kinase 2 (CHK2), has been shown to be detrimental to the potentiation 
of the cytotoxicity of DNA damaging agents and radiotherapy by CHK1 inhibition.
22
 In contrast 
to CHEK1, encoding for the CHK1 protein, the CHEK2 gene is a tumor susceptibility gene, and 
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selective inhibition of CHK2 does not sensitize cancer cells to a range of DNA-damaging 
agents.
23,24
 We also monitored compounds for inhibition of the cell cycle regulatory kinase, 
cyclin dependent kinase 1 (CDK1). Continued cell cycle progression into mitosis is necessary to 
expose cancer cells to the deleterious effects of enhanced DNA damage through checkpoint 
abrogation. Inhibition of cell cycle regulatory kinases such as CDK1, itself an indirect 
downstream target of activated CHK1, would lead to CHK1-independent cell cycle arrest that 
would confound interpretation of the cellular activity of the compounds. In both cases, we 
considered biochemical selectivity of >100-fold a minimum requirement. As lipophilic bases 
present a general risk of ion channel inhibition, we monitored hERG inhibition as a 
representative and clinically relevant off-target during lead optimization. 
Potent and highly selective inhibition of CHK1-dependent effects in human cancer cells was 
considered essential and we specified an IC50 <100 nM for the abrogation of a CHK1-dependent 
etoposide-induced G2/M checkpoint in p53-deficient HT29 human colon cancer cells.
20
 To 
measure CHK1 selective effects in cells, the potency for the CHK1-specific checkpoint 
abrogation was compared with the non-specific anti-proliferative effect of the inhibitors in the 
same cell line, with a minimum requirement of five-fold cellular selectivity.
20
 We used this ratio 
of cellular effects as an integrated surrogate for kinome-wide or other large scale biochemical 
profiling of multiple compounds during lead optimization. The growth of HT29 cells is not 
highly sensitive to selective inhibition of CHK1, thus the ratio of the potency for this CHK1-
independent effect to that for the CHK1-dependent checkpoint abrogation informs on the target 
selectivity of the compounds. Compounds with sufficient cellular potency and selectivity were 
assessed for their ability to potentiate the cytotoxicity of the DNA-damaging agent gemcitabine 
in SW620 human colon cancer cells. CHK1 inhibition has been shown to synergize maximally 
 7 
with anti-metabolites such as gemcitabine compared with other classes of DNA-damaging 
chemotherapies.
25
 
Cellular studies of the tool compound 1 had shown that sustained inhibition of CHK1 signaling 
after administration of the DNA-damaging agent was required for maximal potentiation of the 
efficacy of the cytotoxic agent.
14
 Therefore; compounds with sufficient metabolic stability, 
plasma concentration and pharmacodynamic (PD) duration of action to give 24 h inhibition of 
the target following a single oral dose were sought. Inhibition of the autophosphorylation of 
CHK1 on S296 in HT29 human tumor xenografts was used as a PD measure of target protein 
engagement.
14
  
 
Optimization of in vitro and PK properties  
Compound 3 (Table 1) presented an encouraging starting point for realization of the desired 
clinical candidate profile. While requiring increases in cellular potency and selectivity, the 
compound showed more than 400-fold selectivity for in vitro inhibition of CHK1 over CHK2, 
and was stable in mouse liver microsomes (MLM) (9% metabolized after 30 min; Table S1, 
Supporting Information). To improve on 3 we chose to retain the 5-aminopyrazine-2-carbonitrile 
group, as our extensive structural biology studies to develop the series had shown this group to 
interact optimally with unique protein-bound water molecules in CHK1, conferring high 
selectivity over other kinases.
19
 Basic substitution at C-4 of the pyridine core was retained to 
maximize affinity through potential interactions with polar residues in the ribose binding pocket 
of the CHK1 active site, as we had previously shown for 5-((6-((piperidin-4-
ylmethyl)amino)pyrimidin-4-yl)amino)pyrazine-2-carbonitrile (PDB: 2YM7) and other 
compounds prepared during the identification of 3.
19
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Table 1: In vitro properties of selected 4-amino-substituted methyl 6-((5-cyanopyrazin-2-
yl)amino)nicotinates 
 
No R
1
 R
2 CHK1 
IC50 (nM)
a
 
CHK2 
IC50
 
(M)b 
Checkpoint 
abrogation 
IC50 (nM)
c
 
Cellular 
selectivity 
(fold)
d 
hERG 
(%inhibition
@ 10 M)e 
3 A H 21 (±6) 9.6 (±2.4) 825 (±125) 3.8 39 
5 B - 11  (±0.1) 9.8 (±1.3) 440 (±130) 5.1 55 
6 A Me 19 (±1) - 850 (±450) 4.3 82 
7 C - 2.9 (±0.1) 14
f
 129 (±62) 4.4 69 
8 (s)-D 
 
H 1.0
f
 11 (±5) 21
f
 6.2 58 
9 D
g
 Me 0.5
f,h 
2.2
f 
12 (±6) 7.5 91 
10 (s)-E - 7.0 (±0.3) - 2500
f 
6.8 60 
11 rac-F - 56
b,f 
- 1100
f 
3.5 42 
12 rac-G - 2.2 (±0.3) 5.0
f
 310
f 
3.5 24 
a
 Determined in Caliper microfluidic assay, mean (±SD) for n=2. 
b
 Determined in DELFIA,  
mean (±SD) for n=2. 
c
 Abrogation of etoposide-induced G2 checkpoint arrest in HT29 human 
colon cancer cells, mean (±SD) for n=2. 
d
 Ratio of antiproliferative GI50 (measured in duplicate 
by sulforhodamine B (SRB) assay) to IC50 for CHK1-mediated abrogation of etoposide-induced 
G2 checkpoint arrest in HT29 human cancer cells. 
e
 Inhibition of hERG ion current in HEK cells 
overexpressing hERG ion channel (PatchExpress, Millipore Inc.), single determination at 10 M. 
f
 Single determination. 
g
 Prepared as a mixture of (3s) and (3r) isomers. 
h
 Below tight-binding 
limit of assay. 
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Initially we examined a range of 4-amino-substituted methyl 6-((5-cyanopyrazin-2-
yl)amino)nicotinates to determine the scope for replacing the 4-(piperidine-4-methyl) substituent 
of 3, with selected examples shown in Table 1. Homologation (5) or truncation (7) of the linking 
alkyl chain, and N-methylation (6 and 7) of the piperidine were tolerated, with increased CHK1 
inhibition and cellular potency for 7. The tropane derivatives 8, 9 and 10 showed potent 
inhibition of CHK1 activity (IC50 <10 nM), translating to cellular potency of <100 nM for 8 and 
9 and cellular selectivity exceeding the target threshold of five-fold. The racemic piperidin-2-
methyl analogue 11 retained the profile of 3 while the racemic morpholin-2-yl-methyl derivative 
12 had enhanced biochemical inhibition compared to the piperidines 3 and 11, with more potent 
checkpoint abrogation in cells, but a greater differential between biochemical and cellular 
activities. 
While the increased lipophilicity of the tropane derivatives led to improved potency and 
cellular selectivity, it was also associated with more potent hERG inhibition, particularly for the 
N-methyl derivative 9. In contrast, the racemic morpholin-2-yl-methyl derivative 12 delivered 
enhanced CHK1 affinity with minimal hERG inhibition. Reductions of amine lipophilicity or 
basicity are documented as strategies for reducing hERG activity.
26
 hERG inhibition by a wider 
group of 4-amino-substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates prepared during 
this study, including those exemplified in Table 1, showed a correlation with calculated ALogP 
(Figure 2). Less potent hERG inhibition was more frequently associated with secondary amines 
with a total of 3 hydrogen bond donors (HBD) in the molecule, as shown by compounds 3, 11 
and 12, compared to tertiary amines (2 HBD). This indicated that an increased risk of hERG 
inhibition would be associated with compounds with higher calculated AlogP in this series, but 
 10 
this would need to be balanced with the potential for improved CHK1 cellular potency and 
selectivity with more lipophilic amines. 
 
 
Figure 2. Relationship of hERG inhibition to calculated AlogP and HBD count for 4-amino-
substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates including examples specified in 
Table 1. 
 
During the optimization of the series, selected compounds were screened for metabolic 
stability in MLM and typically showed <30% metabolism of the parent compound after 30 min 
(see Table S1, Supporting Information). The mouse PK profiles of the esters 5 and 7 were 
determined (Table 2). Compound 5 showed moderate oral bioavailability (44%), high volume of 
distribution, and clearance greater than liver blood flow. In vivo clearance was substantially 
increased for the N-methyl piperidine analogue 7 despite similar MLM in vitro stability (26% 
and 28% metabolized after 30 min for 5 and 7, respectively; Table S1, Supporting Information). 
A number of methyl ester-substituted analogues in the related 3-alkoxy-5-(pyridin-2-
 11 
ylamino)pyrazine-2-carbonitrile scaffold
19
 were assessed for stability in human plasma, but no 
evidence for degradation was seen during a 60 min incubation (data not shown). To efficiently 
discriminate compounds on the basis of PK performance, we used a limited sampling strategy 
that compared plasma levels at 1 h and 6 h after i.v. and p.o. dosing
18
 to assess compounds in 
vivo with promising in vitro potency and selectivity, or with structural features important to the 
development of structure-activity relationships. This strategy provided a useful ranking of 
relative oral bioavailability and clearance. Selected compounds were subsequently progressed to 
full PK determinations (Table 2). 
 
Table 2: In vivo mouse PK properties of selected compounds following intravenous (i.v.) or oral 
(p.o.) dosing. 
No. i.v. Dose 
(mg/kg)
 
Cl
a
 
(L/h/kg)
b 
Vss
a
 
(L/kg)
b 
T1/2
a 
(h) 
p.o. Dose 
(mg/kg) 
F
c
 
(%) 
5 5 8.45 60.5 11 5 44 
7 5 54.7 20.2 0.36 5 10 
15 5 7.85 7.25 1.6 5 0 
25 10 6.75 26.8  4.3 10 53 
30 1
 
0.50 1.15 2.0 5
 
16 
36 10 8.25 10.4 3.8 10 10 
38 5 6.35 14.8 2.2 5 68 
40 10 6.70 43.9 8.1 10 68 
41 10 2.75 10.1 3.4 10 84 
4 10 2.65 9.25  2.9 10 105 
a
 Parameters from i.v. PK profile. 
b 
Calculated based on a 20 g mouse body weight. 
c
 Oral 
bioavailability. 
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The crystal structure of 12 bound to CHK1 was determined (PDB: 5F4N, Figure 3). The 2-
aminopyridine core formed hydrogen bonds with Glu85 and Cys87 in the kinase hinge region, as 
seen previously for compounds such as 2 (PDB: 2YM8).
19
 The cyanopyrazine was positioned 
close to the side-chain of Lys38. Importantly, both the nitrile and N-4 of the pyrazine ring were 
positioned to interact with bound water at the entrance to the pocket beyond the gatekeeper 
residue, one of a network of conserved water molecules resulting from the presence of the unique 
polar residue Asn59 in this pocket in CHK1 instead of the more common lipophilic side chains. 
Interactions with these bound waters are a CHK1 selectivity determinant for this and other series 
of CHK1 inhibitors, including other pyrazines.
27,28
 Consistent with this, compounds 3, 5, 6, 7, 9, 
and 12 did not inhibit CDK1 (IC50 >10 M). 
 
Figure 3: Detail of the crystal structure (PDB: 5F4N) showing 12 (green) bound in the CHK1 
ATP site with key residues (grey) and water molecules (red spheres) shown. 
 
The crystallographic model indicated only the (R)-enantiomer of the morpholine to be bound. 
The protonated amine of the morpholine engaged in direct interactions with the side-chain of 
 13 
Glu91 and the main-chain carbonyl of Glu134. In addition, water-mediated interactions to 
Asn135 and Ser147 were observed, illustrating the rich set of potential contacts available to basic 
substituents in this region of the kinase and consistent with the generally high CHK1 affinity of 
the amine variants in Table 1. The morpholine projected towards the main chain of residues 
Leu15, Gly16 and Glu17 in the P-loop but did not form close contacts. At the entrance to the 
ATP-pocket, the C-5 methyl ester substituent lay over the selectivity surface formed by Ser88, 
Gly89 and Gly90. No direct polar interactions of the ester to this moderately hydrophobic 
surface were observed, suggesting scope for optimization of contacts to the protein. Interestingly, 
binding of a second molecule of the inhibitor was detected in the crystal structure at a separate 
hydrophobic site in the N-terminal domain defined by Trp9, Tyr71 and Phe83, however no 
specific polar interactions of the ligand to the protein were evident and this is unlikely to 
represent a biologically relevant site of action. 
In parallel with variation of the C-4 substituent, investigation of substitution at the C-5 position 
of 3 was undertaken. The C-5 ester substituent projects towards solvent and was anticipated to 
provide a handle to optimize in vitro activity and allow for modulation of PK properties. A 
diverse set of substituents from multiple scaffolds has been shown to be capable of binding in 
this region of CHK1.
27
 Compounds were chosen to explore a range of physicochemical 
properties and the resulting structure-activity relationship is illustrated for specific examples of 
different substituent types (Table 3). 
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Table 3: In vitro properties of selected substituted 5-((4-((piperidin-4-ylmethyl)amino)pyridin-2-
yl)amino)pyrazine-2-carbonitriles 
 
No. CHK1   
IC50 (nM)
a
 
Checkpoint 
abrogation 
IC50 (nM)
b
 
Cellular 
selectivity 
(fold)
c
 
hERG 
(%inhibition@
10 M)d 
13 398 (±48) - - - 
14 8.8 (±0.7) 4400 (±400)
e
 5.6 76 
15 55
f,g
 500
 
7.6 26 
16 54 (±4) >10000 - - 
17 4.7 (±0.8)
f
 4000 4.8 52 
18 12 (±1) 3100 4.8 34 
19 50
f,g 
440
 
5.9 59 
20 177 (±8) 600
 
3.0 - 
21 92 (±7) 2500
 
7.6 64 
a
 Determined in Caliper microfluidic assay, mean (±SD) for n=2. 
b
 Abrogation of etoposide-
induced G2 checkpoint arrest in HT29 human colon cancer cells, single determination. 
c
 Ratio of 
antiproliferative GI50 (measured in duplicate by SRB assay) to IC50 for CHK1-mediated 
abrogation of etoposide-induced G2 checkpoint arrest in HT29 human cancer cells. 
d
 Inhibition 
of hERG ion current in HEK cells overexpressing hERG ion channel (PatchExpress, Millipore 
Inc.), single determination at 10 M. e Mean (±SD) for n=2. f Determined in DELFIA assay. g 
Single determination. 
 15 
Replacement of the ester with tertiary alkyl amides led to decreased CHK1 inhibition, e.g. 13 
(Table 3). Secondary alkyl amides, e.g. 14, were better tolerated for CHK1 affinity but had poor 
cellular activity, presumably as a result of the increased polarity and additional HBD compared 
to 3.  Secondary aryl amides such as 15 offered a better range of CHK1 potencies and retained 
some cellular activity with increased cellular selectivity over the ester 3. Compound 15 also 
showed low hERG inhibition despite the addition of the lipophilic aryl substituent. However, the 
PK properties of 15 were discouraging, with high clearance and no detectable oral bioavailability 
(Table 2). Substitution with alkyl, alkenyl and alkynyl groups at C-5 was tolerated for CHK1 
inhibition, with a general preference for the unsaturated functionality at C-5 as represented by 17 
and 18 compared to 16. Aryl and heteroaryl substitution also retained CHK1 inhibition, as for 
example the phenyl 19 and oxadiazole 21 analogues. CHK1 inhibition was sensitive to 
substitution on the C-5 aryl group, as exemplified by 3-fluorophenyl analogue 20. 
As the inhibitors are ATP-competitive, binding to an active conformation of CHK1 kinase 
(Figure 3), we expected a decrease in potency in transferring from the CHK1 biochemical assays 
([ATP] = 30 M) to cells with high endogenous [ATP]. Esters (see Table 1), aryl amides and 
heteroaryl or aryl C-5 substituents generally gave the most favorable ratio of potency for G2/M 
checkpoint abrogation to CHK1 biochemical inhibition (<100-fold). 
The SAR described above showed that identifying a clinical candidate CHK1 inhibitor would 
require balancing the lipophilicity and basicity of the molecules to generate potent CHK1 
biochemical inhibition that translated to effective cellular activity and favorable PK properties, 
while minimizing the risk of ion channel inhibition. We focused on 5-((4-((morpholin-2-
ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles related to morpholine 12. To help 
prioritize the selection of C-5 substituents, three in silico classification models were generated. 
 16 
These considered: CHK1 biochemical potency, ratio of CHK1-dependent cellular activity to 
CHK1 biochemical potency, and inhibition of the hERG ion channel (see Supporting 
Information). The CHK1 biochemical potency model classified compounds with IC50 < 25 nM as 
active, while the model for the ratio of CHK1-dependent cellular and enzyme activities classed 
as desirable those compounds that had a less than 50-fold ratio of cellular to enzyme potency. 
The focus on the translation to cellular potency was driven by the anticipated need for highly 
potent compounds to achieve a low projected dose in humans. As CHK1 inhibitors will be used 
as potentiators of conventional cytotoxic chemotherapy, it is important to minimize non-
mechanism related toxicity to achieve tolerable combination schedules. Lastly, the hERG model 
classified compounds as hERG-inactive if their percentage inhibition was less than 40% @ 10 
M. Virtual molecules were constructed from two chemotypes that varied in one substituent 
position (Figure S1, Supporting Information). The first structure, relevant to this work, was 
based on morpholine 12 with variation of the C-5 substituent. The other structure considered was 
for the previously described series related to compound 1.
18
 Of the substituents selected to 
replace the C-5 group in the virtual library, 135 were selected by medicinal chemists and 1514 
were extracted from commercially available building blocks. The combinatorial library was 
enumerated and, after the application of Lipinski Rule-of-Five heuristics, 1649 virtual structures 
were taken forward for prediction in the three models. The resulting predictions for each of these 
virtual molecules were used to aid selection of compounds for synthesis, using the normalized 
probabilities of satisfying the objectives of each of the three models and visual inspection. 
Representative 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-
carbonitriles related to morpholine 12 are described in Table 4. Replacing the ester of 12 with 
substituted phenyl groups led to the single enantiomers 22-29. In vitro inhibition of CHK1 was 
 17 
higher for the morpholine (R)-enantiomers (compare 22 vs. 23 and 25 vs. 26) consistent with the 
observation of the (R)-enantiomer of 12 bound to CHK1 (Figure 3). Compounds 22, 23, 25 and 
26 were tested for inhibition of CHK2 and retained >100-fold selectivity for CHK1. The cellular 
profiles of these compounds were similar to 12, with no improvement in cellular potency except 
for the 3-fluorophenyl analogue 25. hERG inhibition was increased over 12 for these lipophilic 
analogues. Replacing the C-5-aryl groups by monocyclic heteroaromatics improved cellular 
potency, e.g.  thiazole 30 and N-methyl pyrazole 31. The (R)-enantiomer of the morpholine was 
again preferred (compare 31 vs. 32). Combining the polar pyrazole and lipophilic phenyl 
functionalities in the N-methylindazoles 33 and 34 compromised the cellular potency and 
selectivity compared to the corresponding pyrazole 31. 
The ability of selected compounds to potentiate the efficacy of the cytotoxic drug gemcitabine 
in p53-deficient SW620 human colon cancer cells was investigated (Table 4). The cell active C-
5-aryl analogues 25 and 26 had moderate cellular selectivity, and both potentiated the efficacy of 
gemcitabine. While the thiazole and pyrazole analogues 30-32 strongly potentiated gemcitabine 
cytotoxicity in cells, the indazoles 33 and 34 surprisingly showed minimal activity. The cellular 
selectivities of 33 and 34 were reduced compared with other analogues, suggesting that off-target 
activities may be confounding the CHK1-dependent effects. 
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Table 4: Properties of selected substituted 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-
yl)amino)pyrazine-2-carbonitriles. 
 
No. R
1
 R
2 
R
3 CHK1 
IC50 (nM)
a
 
Checkpoint 
abrogation 
IC50 (nM)
b
 
Cellular 
selectivity 
(fold)
c 
Cellular 
efficacy 
(fold)
d
 
hERG 
%inhibition 
(IC50, M)
e
 
22 (R)-A B 4-OMe 6.4 (±0.1) 900
 
4.3 - 86 
23 (S)-A B 4-OMe 11
f 
1500 4.5 - 73 
24 (S)-A B 4-F 25 (±1) 800
 
6 - 64
 
25 (R)-A B 3-F 6.4 (±0.6) 120 5.8 7.9 71 (8.8) 
26 (S)-A B 3-F 17 (±4)
 
390 10 4.8 71 (8.1) 
27 (R)-A B 3-Cl 5.2 (±1) 600
 
2.2 - 63 
28 (R)-A B 3,4-F2 14 (±0.5) -
 
- - - 
29 (R)-A B 3,5-F2 12 (±2)  630
 
6.7 7.6 38 
30 (R)-A C - 0.5
f,g 
13
 
6.3 8.2 38 (56) 
31 (R)-A D - 0.9
g 
(±0.1)
 
60
 
11 7.4 67 (8.6)
 
32 (S)-A D - 3.2 (±0.8) 400 3.5 8 26 (22) 
33 (R)-A E - 8.5 (±1) 1000 4.2 1.9 51 (16) 
34 (R)-A F - 4.6 (±0.4) 240 3.8 1.9 69 
35 (R)-A G - 0.5
f,g 
280 4.3 - 39 
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36 (S)-A G - 2.2 (±0.4) 180 9.2 8.6 28 (26) 
37 (S)-A H - 2.1 (±0.1) 72 12 5.6 47 (16) 
38 (S)-A -C≡CH - 5.2 (±0.8) 100 29 22 68 (8.2) 
39 rac-(A) -C≡N - 23 (±3)  1600 24 - 8 
40 (S)-A -cyc-Pr - 7.4 (±1.4) 100 9 7.3 79 (6.6) 
4 (R)-A -CF3 - 1.3 (±0.4)
 
30 (±11)
h
 23 17 76 (6.2)
 
41 (R)-A -Cl - 1.9 (±0.8) 157 (±37)
h
 14 18 83 (6.1) 
42 (R)-A -F - 14 (±1) - - - 39 
a
 Determined in Caliper microfluidic assay, mean (±SD) for n≥2. b Abrogation of etoposide-
induced G2 checkpoint arrest in HT29 human colon cancer cells, single determination. 
c
 Ratio of 
antiproliferative GI50 (measured in duplicate by SRB assay) to IC50 for CHK1-mediated 
abrogation of etoposide-induced G2 checkpoint arrest in HT29 human cancer cells. 
d
 Fold-
potentiation of gemcitabine cytotoxicity in SW620 human colon cancer cells, determined as the 
ratio of GI50 (test compound)/GI50 (test compound + fixed dose Gemcitabine) in an SRB assay 
(ref 19). 
e
 Inhibition of hERG ion current in HEK cells overexpressing hERG ion channel 
(PatchExpress, Millipore Inc.), single determination at test concentration of 10 M, IC50 
determination (n=1) in parentheses. 
f
 Single determination in DELFIA assay. 
g
 Below tight-
binding limit of assay. 
h
 Mean (±SD), n≥3. 
 
Key C-5-aryl and C-5-heteroaryl analogues were screened for in vivo PK properties (Table 2). 
The 3-fluorophenyl derivative 25 showed a similar in vivo clearance and bioavailability to the 
ester 5. The thiazole 30 had low in vivo clearance but poor oral bioavailability, presumed to be 
due to poor absorption and consistent with the 20-fold lower volume of distribution for this 
compound. The potent pyrazole 31 was assessed in vivo by limited sampling PK, where a drop in 
plasma levels at 6 h to <20% of those at 1 h indicated a high clearance relative to 5 and the 
compound was not profiled further. 
In tandem with (hetero)aryl groups, non-aryl C-5-substituents were prepared in the 5-((4-
((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile series (Table 4). The 
2-methylbut-3-yn-2-ols 35 and 36 potently inhibited CHK1 with cellular activity and selectivity 
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similar to the aryl substituted analogues. The 1-ethynylcyclopentan-1-ol analogue 37 increased 
potency in vitro and in cells. Both 36 and 37 potentiated the efficacy of gemcitabine in SW620 
cells but the PK profile of 36 showed high clearance and low oral bioavailability (Table 2). 
The terminal alkyne derivative 38 was found to retain cellular activity, and to have 
exceptionally high cellular selectivity compared to other compounds in this series. The 
potentiation of the anti-proliferative effects of gemcitabine by the alkyne 38 was also increased. 
The nitrile analogue 39 gave very high cellular selectivity but with reduced biochemical and 
cellular potency. Other small substituents at C-5 were investigated (Table 4) and the structure-
activity relationship for the potentiation of gemcitabine cytoxicity in SW620 human colon cancer 
cells revealed an inverse correlation to the size of the C-5 substituent, as measured by molecular 
weight or heavy atom count (Figure 4). The cellular selectivity for CHK1-mediated effects 
followed a similar trend. The crystal structure of 12 bound to CHK1 (Figure 3) indicated that 
substitution at the C-5-position would become directed into solvent with increasing size rather 
than making contacts with the CHK1 protein. We therefore speculate that the structure-activity 
relationships for high cellular efficacy and selectivity reflected confounding off-target 
interactions, possibly one or more kinases, that increased with increasing size of the C-5-
substituent and interfered with the ability of the CHK1 inhibitor to potentiate genotoxic efficacy. 
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Figure 4. Relationship of efficacy and selectivity in SW620 colon cancer cells to molecular 
weight for 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles 
with C-5 substituents of various sizes, exemplified in Table 4. Points are color-coded by CHK1 
cellular selectivity (red – low, green – high) and labelled with compound identifiers. 
 
Among the smaller substituents investigated at C-5, the cyclopropyl analogue 40 maintained 
potency but with decreased cellular selectivity and efficacy. In contrast, both the trifluoromethyl- 
4 and chloro-derivative 41 had excellent potency and cellular selectivity, and were strong 
potentiators of gemcitabine efficacy in cancer cells. Consistent with the cellular profile, these 
compounds were more than 1000-fold selective for CHK1 over CHK2 and CDK1. The 
41
38
4
40
36
32
31
25
30
26
37
29
33/34
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importance of the presence of a suitable C-5 substituent for CHK1 affinity was shown by the 
fluoro analogue 42 which was ten-fold less potent than 4. Although more potent and efficacious 
in cells, the smaller and more lipophilic C-5 substituents were associated with micromolar hERG 
inhibition. This was balanced by an improvement in PK properties. Thus, the terminal alkyne 38 
and cyclopropane 40 had improved oral bioavailability compared to 5, while both the 
trifluoromethyl 4 and chloro analogue 41 had substantially reduced in vivo clearance and 
increased oral bioavailability (Table 2). Inhibition of CYP450 enzymes was determined for 
selected analogues, and compounds 36, 38, 40, 41 and 4 all showed IC50 >10 M against the 6 
isoforms tested (1A2, 2A6, 2C9, 2C19, 2D6, 3A4). 
 
Optimization of in vivo target engagement and efficacy 
In parallel with the optimization of in vitro and PK properties, the PD properties of this series 
of CHK1 inhibitors were assessed in vivo. Following DNA damage, CHK1 is activated through 
phosphorylation on Ser317 and Ser345 by the upstream kinase ATR, and undergoes 
autophosphorylation on Ser296. We therefore chose inhibition of the gemcitabine-induced 
CHK1 Ser296 autophosphorylation as a direct PD biomarker of CHK1 inhibition in vivo. 
Selected compounds with moderate to good oral bioavailability, high cellular selectivity and 
gemcitabine-potentiating efficacy were assessed for tolerability in mice when administered in 
combination with gemcitabine (60 mg/kg i.v.). The compounds were then tested at the maximum 
tolerated combination dose for their ability to inhibit gemcitabine-induced pSer296 CHK1 in 
SW620 human colon cancer xenografts. It has been shown that maximum potentiation of 
genotoxic efficacy in cells and in vivo requires sustained inhibition of CHK1 signaling to prevent 
effective tumor cell DNA repair, and inhibition of CHK1 for at least 24 – 48 h following 
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administration may be desirable.
14,15
 We therefore sought compounds showing robust pSer296 
inhibition up to 24 h following a single oral dose. 
The dose of compound 25 (80 mg/kg) was restricted by toxicity, although a partial inhibition 
of the CHK1 pSer296 signal was seen at 6 h (data not shown). In contrast, single doses of 
compounds 38 (300 mg/kg), 41 (300 mg/kg), and 4 (300 mg/kg) were very well tolerated. 
Compound 38 inhibited the gemcitabine-induced autophosphorylation of CHK1 at 6 h (not 
shown), but CHK1 kinase activity had recovered by 24 h (Figure 5A). In contrast, the two 
compounds 41 and 4 inhibited gemcitabine-induced pS296 CHK1 for up to 24 h (Figure 5B, C).  
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Figure 5: Inhibition of gemcitabine (60 mg/kg i.v.)-induced pSer296 CHK1 autophosphorylation 
at 24 h by 300 mg/kg p.o. of A) 38, B) 41 and C) 4 in SW620 human colon cancer xenografts. 
Dashed line indicates where western blot image has been cut. D) Total inhibitor concentrations 
of 38, 41 and 4 in plasma and SW620 tumor xenografts at 24 h after a single 300 mg/kg p.o. dose 
(mean±SD, n=3). 
Inhibitor concentrations at 24 h were measured in plasma and the tumor xenografts (Figure 
5D). Plasma levels of between 4 – 8 M were seen for 38, 41 and 4. Similar levels of 38 were 
observed despite the higher clearance of this compound compared with 41 and 4 (Table 2). 
Distribution to tumor tissue was seen for all compounds, with 4 achieving the highest tumor 
concentration. 
The antitumor efficacies of 41 and 4 were investigated in combination with gemcitabine in 
HT29 human colon cancer xenografts. The dosing schedule was selected based on our previous 
studies of the oral CHK1 tool compound 1
14
 and involved the administration of two doses of the 
CHK1 inhibitors at 24 and 48 h after gemcitabine (100 mg/kg i.v.) in each of three, weekly 
treatment cycles. Compounds 41 and 4 were dosed at their maximum tolerated dose (MTD) (150 
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mg.kg p.o.) for this schedule in the xenograft tumor model (Figure 6). Both compounds were 
well tolerated in combination with no significant decrease in body weight. A strong potentiation 
of the anti-tumor effect of gemcitabine was seen, consistent with the cell-based studies (Table 4), 
with minimal effects of the CHK1 inhibitors alone in this model. At these doses, tumor 
regressions were observed in 83% (41) and 100% (4) of the combination-treated cohorts at day 
17 immediately following completion of the final treatment cycle. 
 
 
Figure 6: Anti-tumor efficacies of 41 (150 mg/kg p.o.) and 4 (150 mg/kg p.o.) in combination 
with gemcitabine (100 mg/kg i.v.) in HT29 colon cancer xenografts. The CHK1 inhibitors were 
administered as suspensions in DMSO-Tween80-PEG400-water (0.05:0.2:0.65:0.1) 24 and 48 h 
after gemcitabine in each of three weekly treatment cycles. Inset: body weights of cohorts as 
described in main figure. N=4-6 per cohort. 
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The in vitro and in vivo PK properties of 41 and 4 were investigated further (Table 5). Both 
compounds had low oral bioavailability in rats. Although both were high clearance compounds, 
4 had a lower clearance than 41. Pleasingly, determination of the intrinsic clearance (CLint) in 
hepatocytes showed both compounds were substantially more stable in human hepatocytes than 
mouse, and 4 was more stable in human than rat and dog hepatocytes. In particular, 4 had a 
favorable low human hepatocyte CLint. Predictions of human clearance were made using 
physiological-based PK (PBPK) modelling
29
 and suggested that 4 would have a clearance in 
humans of 6% liver blood flow. 
 
Table 5: Additional in vivo and in vitro PK data for 41 and 4. 
  41  4  
Rat PK 
 
CL (L/h/kg) 
Vss (L/kg) 
F (%) 
5.17 
7.45 
22 
3.50 
4.60 
38 
Hepatocyte CLint 
(L/min/106 cells)a 
 
Mouse
b
 
Rat 
Dog 
Human
d
 
22.1 (±2.6) 
n.d
c
 
n.d
c
 
4.82 (±0.91) 
25.7 (±3.4) 
43.4 (±9.96) 
55.0 (±2.1) 
2.72 (±0.61) 
a
 Determined at Cyprotex. Incubations at 3 M. Mean (±SE) b Incubations in male CD-1 
mouse hepatocytes. 
c
 not determined. 
d
 Incubations in mixed gender human hepatocytes. 
 
In vitro and in vivo profile of compound 4 
Compound 4 was further profiled in vitro and in vivo. The solubility of 4 in pure water was 
0.09 mg mL
-1
, rising to 1.5 mg mL
-1
 in pH 6.5 phosphate buffer, consistent with the moderate 
basicity (pKa = 7.87 ±0.07)
30
 and lipophilicity (LogD7.4 = 1.47 ±0.04)
30
 and indicating good 
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prospects for formulation as a salt. Compound 4 showed passive permeability across a CaCo2 
cell monolayer (Pe = 25 x10
-6
 cms
-1
). The plasma protein binding of 4 was moderate (mouse Fu = 
0.19; human Fu = 0.21, measured using dialysis with pH control). No change in the metabolic 
stability of 4 was observed in human liver microsomes in the presence and absence of 
glutathione, indicating that 4 does not undergo metabolic activation. While some electron-
deficient heterocyclic nitriles have been reported to be chemically reactive under physiological 
conditions,
31 
we speculate that the balanced electronic donor-acceptor substitution pattern of the 
5-aminopyrazine-2-carbonitrile prevents this reactivity. Compound 4 was not metabolized by 
human aldehyde oxidase. 
The kinome selectivity of 4 was assessed against a panel of 124 representative kinases in 
substrate phosphorylation assays ([ATP] = Km,ATP).
32
 Compound 4 showed <50% inhibition at 10 
M for 85/121 kinases, representing a selectivity for CHK1 inhibition of >5000-fold over these 
enzymes, while 12/124 (including CHK1) showed >80% inhibition at 10 M (Table S2, 
Supporting Information). The activity of these enzymes, along with the potential off-targets 
CDK1/2 and 5'-AMP-activated protein kinase (AMPK)
33
 were titrated (Table S3, Supporting 
Information). Sub-micromolar activity was identified for seven kinases in this panel, with 4 
showing 100-fold selectivity for CHK1 over the most potent off-target kinase activity identified 
(mitogen-activated protein kinase 15, ERK8) and more than 200-fold selectivity for CHK1 over 
other kinases tested. These data confirmed the expectation of high CHK1 selectivity from the 
cellular selectivity of 4. While medium-throughput whole-kinome profiling during lead 
optimization is feasible, interpretation of the functional relevance of off-target binding assays 
remains difficult.
34
 Our experience with this inhibitor series shows that appropriate cell-based 
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mechanistic assays can drive compounds towards high kinome selectivity based on an integrative 
assessment of on- vs. off-target outcomes in cancer cell lines.
 
The ability of compound 4 to potentiate the anti-cancer efficacy of DNA-damaging agents was 
determined in a wider range of cancer cell lines (Supporting Information, Table S4).
21
 
Potentiation of the efficacy of the anti-metabolite gemcitabine (8 – 23-fold) was significantly 
greater than that for SN38 (1.8 – 3-fold), the active metabolite of the clinical topoisomerase 1 
inhibitor irinotecan. Importantly, in addition to efficacy in colon cancer cell lines, compound 4 
strongly potentiated gemcitabine efficacy in non-small cell lung cancer (NSCLC) and pancreatic 
cancer cell lines. These represent clinical indications where gemcitabine is part of current 
chemotherapy regimens, and where tumors have a high frequency of p53 mutation or loss-of-
function.
35,36
 Compromise of the p53-dependent DDR checkpoint may enhance the effectiveness 
of CHK1 inhibition in combination with  genotoxic agents.
7 
 The inhibition of CHK1 and anti-
tumor efficacy of 4 was confirmed in NSCLC and pancreatic cancer tumor xenografts.  In 
particular, 4 potentiated the efficacy of a gemcitabine and carboplatin combination in RAS 
mutant Calu6 human NSCLC xenografts.
21
 In vivo efficacy in combination with gemcitabine was 
further demonstrated in the KPC1 genetically engineered mouse model (GEMM) of p53- and V-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)-deficient pancreatic ductal 
adenocarcinoma.
37
 In cells derived from this model, 4 potentiated the anti-proliferative effect of 
gemcitabine 18-fold in vitro. Allografts from established KPC1 mouse tumors were grown 
subcutaneously in female NCr athymic mice, and treated with gemcitabine and three dose levels 
of 4 using the schedule developed during lead optimization. Some single agent efficacy of the 
highest dose of CHK1 inhibitor was observed in this model in addition to dose-dependent 
potentiation of gemcitabine efficacy (Figure 7).
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Figure 7: 4 (150 mg/kg p.o.) potentiates the tumor growth delay of gemcitabine in allograft 
KPC1 p53- and KRAS-deficient mouse pancreatic adenocarcinomas.
37
 N=8 per cohort. Red 
arrow = gemcitabine dosed; blue arrow = 4 dosed. 
Single agent CHK1 inhibition has recently been identified as a potential therapeutic strategy 
for MYC-driven tumors that rely on the CHK1-mediated DDR pathway as a result of replication 
stress.
9,10
 We therefore assessed the efficacy of compound 4 in vivo in a GEMM of pediatric 
MYCN-driven neuroblastoma.
38
 After treatment for 7 days with compound 4 (150 mg/kg p.o. 
UID), the weights of excised abdominal tumors were reduced compared with vehicle treated 
cohorts (T/C = 13%) and an individual mouse assessed by magnetic resonance imaging (MRI)
39
 
before and after dosing of 4 showed 85% reduction in the pre-treatment tumor volume (Figure 
8). Single agent efficacy of 4 was also demonstrated in an Eµ-Myc driven mouse model of B-cell 
lymphoma.
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Figure 8: 4 (150 mg/kg p.o. UID for 7 d) inhibits tumor growth in the TH-MYCN GEMM of 
neuroblastoma.
38
 A) Comparison of tumor weights for vehicle- and compound-treated cohorts 
(Mean ±SEM, n=8); B) Pre- and post-treatment T2-weighted MRI
39
 assessment of an abdominal 
tumor in a single mouse treated with 4. k = kidney 
 
Dose titration of 4 in combination with gemcitabine (100 mg/kg i.v.) was carried out in HT29 
colon cancer xenografts to establish in vivo PK-PD relationships and determine a minimum 
effective dose in this preclinical tumor model. Compound 4 showed an increase in plasma and 
tumor concentrations between 3 – 100 mg/kg p.o.21 Modulation of the pSer296 CHK1 
autophosphorylation was assessed by western blot from tumor lysates at 24 h after a single dose 
of 4, administered 24 h after gemcitabine. Inhibition of pSer296 CHK1 at this time point was 
observed from 12.5 – 100 mg/kg dose of 4 with no effect for lower doses. Dose-dependent 
potentiation of gemcitabine efficacy in this model was also observed from doses of 12.5 mg/kg 
upwards.
21
 Calculation of the plasma free drug levels of 4 from the PD dose-titration suggested 
that complete CHK1 inhibition for 24 h after dosing of 4 was associated with achieving free drug 
levels of at least 15 nM at 24 h. Single species scaling from mouse
40
 and PBPK methods using 
Simcyp with limited and full simulations were used to predict human clearance and a dose 
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equivalent to the minimum effective dose of 12.5 mg/kg in mice. Both methods predicted that 4 
would show CHK1-dependent effects below 1 mg/kg in humans. For example, the simulated PK 
profile for a 25 mg total dose in humans predicted a plasma Cmax, free of ca. 70 nM and C24h, free of 
ca. 30 nM, suggesting an acceptable window over the in vitro potential for hERG inhibition 
existed at doses predicted to give free concentrations exceeding those relevant to preclinical 
biological activity in the human tumor model. Further profiling of cardiac ion channel inhibition 
was conducted, and 4 showed no inhibition (IC50 >10 M) for seven other K, Ca and Na ion 
channels (Table S5, Supporting Information).
41
 The therapeutic window over potential 
cardiovascular effects was confirmed by an in vivo cardiovascular pharmacology study (data not 
shown). Compound 4 was selected for progression to preclinical development. 
 
Chemistry. General procedures were developed for the synthesis of the C-4 amino-substituted 
methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates 3 and 5-12 (Scheme 1). Methyl 4,6-
dichloronicotinate (43) underwent selective SNAr reaction with a range of amines to give the 
methyl 4-amino-6-chloronicotinate derivatives (44). The substituted pyrazine was introduced by 
Buchwald couplings of the chlorides 44 with 5-aminopyrazine-2-carbonitrile. The majority of 
compounds were prepared using tris(dibenzylideneacetone)dipalladium(0) and xantphos as the 
catalyst precursors and cesium carbonate as the base. When these conditions gave poor yields, 
we found that using tris(dibenzylideneacetone)dipalladium(0), 2,2'-bis(diphenylphosphino)-1,1'-
binaphthyl) (BINAP) and sodium tert-butoxide was successful. Deprotection of N-tert-
butyloxycarbonyl (N-Boc) groups with trifluoroacetic acid was applied where required to 
generate the test compounds. 
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Scheme 1. Preparation of compounds 3, 5-15 and 21.
a
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a
 Reagents and conditions: (i) R
1
NH2, Et3N, 
n
BuOH, 120 
o
C (microwave irradiation), 1.5 h; (ii) 
5-aminopyrazine-2-carbonitrile, Pd2(dba)3, BINAP, NaO
t
Bu, toluene, 130 
o
C (microwave 
irradiation), 30  min; (iii) 5-aminopyrazine-2-carbonitrile, Pd2(dba)3, xantphos, Cs2CO3, toluene, 
130 
o
C (microwave irradiation), 30  min; (iv) CF3CO2H, CH2Cl2, r.t.; (v) NaOH, H2O, MeOH, 
r.t. 3 h; (vi) MeNH2 (2M, THF), HATU, 
i
Pr2NEt, DMF, r.t., 18 h; (vii) 5-aminopyrazine-2-
carbonitrile, Pd2(dba)3, xantphos, Cs2CO3, toluene/DMF (1:1), 130 
o
C (microwave irradiation), 
120  min; (viii) (a) LiOH, H2O, 
t
BuOH, r.t, 4 d, (b) R
2
NH2, TBTU, r.t., 18 h; (ix) (a) LiI, 
pyridine, 150 
o
C (microwave irradiation), 2.5 h, (b) N'-hydroxyacetimidamide, HATU, 
i
Pr2NEt, 
DMF, r.t. 18 h, (c) pyridine, 120 
o
C (microwave irradiation), 1 h. 
 
The above procedures were adapted for the synthesis of the C-5 amide substituted analogues 
13-15 and the C-5 1,2,4-oxadiazole substituted analogue 21 (Scheme 1). The appropriate methyl 
4-amino-6-chloronicotinate (44; R
1
=N-Boc-piperidin-4-ylmethyl) was hydrolysed to the acid 45. 
The acid 45 was converted to the amide under standard conditions and the pyrazine introduced 
by Buchwald reaction as before, to give 13 after deprotection. Secondary amides 14 and 15 were 
prepared from the intermediate ester (44; R
1
=N-Boc-piperidin-4-ylmethyl) through conversion to 
46 before hydrolysis and coupling of the crude acid to aniline or ethylamine. Deprotection gave 
14 and 15. Alternatively, the intermediate methyl ester 46 was converted to the acid by SN2 
dealkylation with lithium iodide in pyridine. The crude acid was coupled with N'-
hydroxyacetimidamide and cyclized at high temperature to yield the 1,2,4-oxadiazole 21. 
General procedures were developed for the synthesis of the C-5 alkenyl, aryl and heteroaryl 
substituted analogues 17, 19, 20, 22-34 (Scheme 2). 2-Chloropyridin-4-amine (47) was iodinated 
to give 2-chloro-5-iodopyridin-4-amine (48).
42
 Introduction of C-4 amine substituents was 
effected by alkylation of the sodium anion of 48 with either tert-butyl 4-
(bromomethyl)piperidine-1-carboxylate or the appropriate enantiomerically pure tert-butyl 2-
((tosyloxy)methyl)morpholine-4-carboxylates to give the substituted iodopyridines 49. Suzuki 
couplings to the iodides 49 using vinyl, aryl and heteroaryl boronic acids or boronate esters 
generated the chloropyridines 50. In turn, these were subject to Buchwald coupling with 5-
 34 
aminopyrazine-2-carbonitrile followed by N-Boc deprotection to give the test compounds. For 
the thiazole analogue 30, the Suzuki coupling step was replaced with a Stille coupling using 5-
methyl-2-(tributylstannyl)thiazole. 
 
Scheme 2. Preparation of compounds 16-20 and 22-38.
a
 
 
a
 Reagents and conditions: (i) ICl, KOAc, AcOH, 70 
o
C, 5 h; (ii) R
1
Br or R
1
OTs, NaH, DMF, 
80 
o
C, 2 h; (iii) R
2
B(OR)2, (Ph3P)4Pd, Na2CO3 (0.5M, H2O), MeCN, 100 
o
C (microwave 
irradiation), 20 min; (iv) 5-aminopyrazine-2-carbonitrile, Pd2(dba)3, xantphos, Cs2CO3, toluene, 
150 
o
C (microwave irradiation), 1 h; (v) CF3CO2H, CH2Cl2, r.t.; (vi) 5-methyl-2-
(tributylstannyl)thiazole, (Ph3P)4Pd, toluene, 90 
o
C, 18 h; (vii) HCl, dioxane, r.t., 1 h; (viii) 
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R
3
CCH, CuI, Pd(Ph3P)2Cl2, Et3N, DMF, 120 
o
C (microwave irradiation), 10 min; (ix) H2, 10% 
Pd/C, EtOH, r.t., 18 h. 
 
The above procedures were adapted for the synthesis of the C-5 alkynyl substituted analogues 
18 and 35-38 (Scheme 2). The iodopyridines 49 were subject to Sonogashira couplings to give 
the alkynylpyridines 52, followed by introduction of the pyrazine by Buchwald reaction and N-
deprotection. Synthesis of the C-5 alkyl substituted analogue 16 was achieved starting from the 
appropriate protected 5-alkynyl-2-chloropyridine (52; R
1
 = N-Boc-piperidin-4-yl-methyl, R
3
 = 
t
BuMe2SiOCH2), which was coupled to 5-aminopyrazine-2-carbonitrile using Buchwald 
conditions, followed by hydrogenation of the alkyne to the saturated alkyl chain (Scheme 2). The 
N-Boc and O-tert-butyl-dimethylsilyl protecting groups were removed using trifluoroacetic acid. 
 
Scheme 3. Preparation of compounds 39 and 40.
a
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a
 Reagents and conditions: (i) tert-Butyl (rac)-2-(aminomethyl)morpholine-4-carboxylate, 
Et3N, 
n
BuOH, 120 
o
C (microwave irradiation), 1.5 h; (ii) (CF3CO)2, Et3N, CH2Cl2, 0 
o
C, 30 min; 
(iii) 5-aminopyrazine-2-carbonitrile, Pd2(dba)3, BINAP, K3PO4, dioxane, 150 
o
C (microwave 
irradiation), 1 h; (iv) CF3CO2H, CH2Cl2, r.t.; (v) cyclopropylboronic acid pinacol ester, 
(Ph3P)4Pd, Na2CO3 (0.5M, H2O), MeCN, 130 
o
C (microwave irradiation), 1.5 h; (vi) 5-
aminopyrazine-2-carbonitrile, Pd2(dba)3, xantphos, Cs2CO3, dioxane, 130 
o
C (microwave 
irradiation), 45 min. 
Synthesis of the C-5 nitrile analogue 39 was begun by selective SNAr displacement of 4,6-
dichloronicotinamide 53 using tert-butyl (rac)-2-(aminomethyl)morpholine-4-carboxylate to 
yield the chloropyridine 54 (Scheme 3). The nitrile was then introduced by dehydration of the 
primary amide using trifluoroacetic anhydride. Buchwald coupling to install the pyrazine and N-
deprotection followed as before.  
Synthesis of the C-5 cyclopropyl analogue 40 was achieved by reacting the appropriate 5-
iodopyridine (49; R
1
 = (R)-N-Boc-morpholin-2-yl-methyl) with cyclopropylboronic acid pinacol 
ester under Suzuki coupling conditions to give 55, followed by Buchwald coupling of the 
pyrazine and N-deprotection (Scheme 3). 
General procedures were developed for the synthesis of the C-5 chloro- and fluoro-substituted 
Aanalogues 41 and 42 (Scheme 4). Commercially available pyridines 56 and 57 were N-
alkylated with tert-butyl (R)-2-((tosyloxy)methyl)morpholine-4-carboxylate to give the 
chloropyridines 58 and 59, respectively, which were subject to Buchwald coupling and N-
deprotection to generate 41 and 42. 
Synthesis of the C-5 trifluoromethyl substituted analogue 4 was begun by conversion of the 
commercially available 2-chloro-5-(trifluoromethyl)isonicotinic acid (60) to the 4-aminopyridine 
61 by a Curtius-Hoffman reaction sequence
43
 (Scheme 4). N-Alkylation using tert-butyl (R)-2-
((tosyloxy)methyl)morpholine-4-carboxylate, followed by Buchwald coupling of 5-
aminopyrazine-2-carbonitrile and morpholine N-deprotection completed the synthesis of 4. 
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Scheme 4. Preparation of compounds 4, 41 and 42.
a
 
 
a
 Reagents and conditions: (i) tert-Butyl (R)-2-((tosyloxy)methyl)morpholine-4-carboxylate, 
NaH, DMF, 80 
o
C, 2.5 h; (ii) 5-aminopyrazine-2-carbonitrile, Pd2(dba)3, xantphos, Cs2CO3, 
dioxane, 150 
o
C (microwave irradiation), 60  min; (iii) CF3CO2H, CH2Cl2, r.t.; (iv) diphenyl 
phosphorazidate, Et3N, 
t
BuOH, toluene, 105 
o
C, 5 h; (v) 5-aminopyrazine-2-carbonitrile, 
Pd2(dba)3, BINAP, Cs2CO3, dioxane, 150 
o
C (microwave irradiation), 1 h; (vi) CF3CO2H, 
i
Pr3SiH, CH2Cl2, r.t., 1 h.  
 
CONCLUSION 
Multi-parameter lead optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-
carbonitriles was conducted to identify potent and selective CHK1 inhibitors that potentiated the 
efficacy of genotoxic agents in vitro and in vivo. The use of cellular mechanism of action assays 
to give an integrated assessment of compound selectivity was critical to drive the in vitro 
optimization of the series and resulted in a highly CHK1 selective, ATP-competitive inhibitor. In 
particular, selective effects in cells were dependent on the size of a substituent directed away 
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from the CHK1 kinase active site. Lipophilicity and basicity were observed to drive both CHK1 
potency and off-target hERG ion channel activity with some overlapping structure-activity 
relationships. An acceptable therapeutic window over hERG inhibition was achieved by 
identifying molecules which gave potent CHK1 affinity and cellular activity through minimizing 
the size of the C-5 substituent. 
Augmenting in vitro assays with an efficient in vivo PK screening strategy was important to 
select compounds with favorable oral PK properties from this series.  In tandem, in vivo PD 
studies identified compounds giving prolonged target engagement following single oral dose, 
which is anticipated as important for the clinical success of CHK1 inhibition in combination with 
genotoxic drugs. Compounds with the desired PK-PD profile demonstrated efficacy in vivo in 
this setting. Compound 4 was profiled in depth and showed a favorable physicochemical, PK and 
PD-efficacy profile. The high affinity and low predicted human clearance of the compound 
supported predictions of low doses to humans. This mitigated the residual in vitro hERG activity, 
confirmed by an in vivo cardiovascular pharmacology study (data not shown). Compound 4 
(CCT245737) was selected for progression to preclinical development.
 
 
EXPERIMENTAL SECTION 
Chemistry: General Information. Reactions were carried out under N2. Organic solutions 
were dried over magnesium sulfate or sodium sulfate. Starting materials and solvents were 
purchased from commercial suppliers and were used without further purification. Reactions 
heated by microwave irradiation were carried out using a Biotage Initiator microwave reactor. 
Flash silica column chromatography was performed using Merck silica gel 60 (0.025-0.04 mm). 
Gradient silica column chromatography was performed with a Biotage SP1 medium pressure 
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chromatography system, using prepacked silica gel cartridges. Ion exchange chromatography 
was performed using Isolute Flash SCX-II (acidic) or Flash NH2 (basic) resin cartridges. 
1
H 
NMR spectra were recorded on a Bruker AMX500 instrument at 500 MHz or on a Bruker 
Avance instrument at 400MHz using internal deuterium locks. Chemical shifts (δ) are reported 
relative to TMS (δ=0) and/or referenced to the solvent in which they were measured. Compounds 
were assessed for purity by tandem HPLC-MS. Combined HPLC-MS analyses were recorded 
using a Waters Alliance 2795 separations module and Waters/Micromass LCT mass detector 
with HPLC performed using Supelco DISCOVERY C18, 50 mm x 4.6 mm or 30 mm x 4.6 mm 
i.d. columns, or using an Agilent 6210 TOF HPLC-MS with a Phenomenex Gemini 3 μm C18 (3 
cm x 4.6 mm i.d.) column. Both HPLC systems were run at a temperature of 22 C with gradient 
elution of 10-90% MeOH/0.1% aqueous formic acid at a flow rate of 1 mL/min and a run time of 
3.5, 4 or 6 min. UV detection was at 254 nm and ionisation was by positive or negative ion 
electrospray. The molecular weight scan range was 50-1000 amu. Biologically evaluated 
compounds gave >95% purity as determined by these methods. 
Synthesis of compound 4. (R)-5-(4-(Morpholin-2-ylmethylamino)-5-(trifluoromethyl)pyridin-
2-ylamino)pyrazine-2-carbonitrile (4). NaH (60% in oil, 33 mg, 0.81 mmol) was added to a 
solution of 2-chloro-5-(trifluoromethyl)pyridin-4-amine (61) (80 mg, 0.41 mmol) in DMF (4 
mL) and the mixture was stirred at rt for 10 min. The temperature was raised to 80 °C and (R)-
tert-butyl 2-(tosyloxymethyl)morpholine-4-carboxylate (181 mg, 0.488 mmol) was added 
portion wise. The reaction mixture was stirred at 80 °C for 2 h, then cooled to rt. The mixture 
was partitioned between saturated aqueous NaHCO3 and EtOAc. The combined organic layers 
were washed with brine, dried, filtered and concentrated. Flash column chromatography, eluting 
with a gradient of 10–20% EtOAc–hexanes, gave (S)-tert-butyl 2-((2-chloro-5-
 40 
(trifluoromethyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate (118 mg, 0.30 mmol, 
73%). 
1
H NMR (CDCl3, 500 MHz) δ 8.24 (s, 1H), 6.61 (s, 1H), 5.32 (br s, 1H), 3.96 – 3.94 (m, 
3H), 3.70 – 3.65 (m, 1H), 3.58 (ddd, J = 11.5, 11.5 and 2.6 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.21 – 
3.18 (m, 1H), 2.99 (br s, 1H), 2.77 (br s, 1H), 1.49 (s, 9H); 
13
C NMR (CD3OD, 125 MHz) δ 
155.4, 154.3, 152.6, 147.4 (q, JCF = 6.1 Hz) , 124.7 (q, JCF = 269.8 Hz), 108.6 (q, JCF = 30.2 Hz), 
106.0, 79.6, 73.8, 66.2, 46.2 (br), 44.5, 45.0 (br), 28.4 (3C); LCMS (3.5 min) tR = 2.62 min; m/z 
(ESI
+
) 396 (M+H
+
); HRMS m/z calcd for C16H22ClF3N3O3 (M + H) 396.1296, found 396.1292. 
Dioxane (2.53 mL) was added to a mixture of (S)-tert-butyl 2-((2-chloro-5-
(trifluoromethyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate (100 mg, 0.25 mmol), 5-
aminopyrazine-2-carbonitrile (42.5 mg, 0.35 mmol), Pd2dba3 (19 mg, 0.02 mmol), Cs2CO3 (165 
mg, 0.50 mmol) and BINAP (25 mg, 0.04 mmol). Argon was bubbled through the suspension for 
5 min. The mixture was heated by microwave irradiation at 150 °C for 1 h. The reaction mixture 
was cooled to rt and purified by ion exchange chromatography on SCX-II acidic resin, eluting 
with MeOH then 2M NH3 in MeOH. The basic fractions were combined and concentrated. 
Preparative thin layer chromatography, eluting with 2% MeOH–CH2Cl2, gave (S)-tert-butyl 2-
((2-(5-cyanopyrazin-2-ylamino)-5-(trifluoromethyl)pyridin-4-ylamino)methyl)morpholine-4-
carboxylate (69 mg, 0.144 mmol, 57%). 
1
H NMR (CD3OD, 500 MHz) δ 8.97 (br s, 1H), 8.66 (br 
s, 1H), 8.19 (s, 1H), 7.34 (br s, 1H), 4.04 (br d, J = 12.9 Hz, 1H), 3.94 (br d, J = 10.5 Hz, 1H), 
3.86 (ddd, J = 13.4, 1.3 and 1.3 Hz, 1H), 3.72 – 3.71 (m, 1H), 3.54 (ddd, J = 11.7, 11.7 and 2.5 
Hz, 1H), 3.46 – 3.39 (m, 2H), 3.00 (br s, 1H), 2.77 (br s, 1H), 1.47 (s, 9H); 13C NMR ((CD3)2SO, 
125 MHz) δ 156.2, 154.3, 152.3, 152.0, 147.6, 146.4 (q, JCF = 5.2 Hz) , 137.3, 125.2 (q, JCF = 
271.8 Hz), 119.2, 117.5, 104.9 (q, JCF = 21.0 Hz), 93.9, 79.6, 73.0, 66.3, 46.7 (br), 44.9 (br), 43.7 
(br), 28.4 (3C); LCMS (3.5 min) tR = 2.51 min; m/z (ESI
+
) 480 (M+H
+
); HRMS calcd for 
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C21H25F3N7O3 (M + H) 480.1966, found 480.1971. The above procedures were repeated to 
produce additional starting material for the next stage: CF3CO2H (4.7 mL, 61 mmol) was added 
to a solution of (S)-tert-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(trifluoromethyl)pyridin-4-
ylamino)methyl)-morpholine-4-carboxylate (206 mg, 0.4 mmol) and (
i
Pr)3SiH (0.56 mL, 2.8 
mmol) in CH2Cl2 (50 mL). The solution was stirred at rt for 1 h then solvents were removed by 
evaporation. The residue was purified by ion exchange chromatography on SCX-II acidic resin, 
eluting with MeOH then 2M NH3 in MeOH. The basic fractions were combined and 
concentrated. Trituration with 10% MeOH–CH2Cl2 gave 4 (116 mg) as an amorphous solid. 
Purification of the mother liquids by preparative thin layer chromatography, eluting with 5% 
MeOH–CH2Cl2, gave additional material (22 mg) of similar purity. The two batches of material 
obtained were combined, re-dissolved in MeOH, and solvent was removed by evaporation to 
give 4 (138 mg, 0.364 mmol, 85%) as a pale yellow amorphous solid. 
1
H NMR ((CD3)2SO, 500 
MHz) δ 10.7 (br s, 1H), 9.10 (d, J = 1.4 Hz, 1H), 8.77 (d, J = 1.4 Hz, 1H), 8.20 (s, 1H), 7.19 (s, 
1H), 6.32 (br t, J = 5.5 Hz, 1H), 3.75 (br d, J = 11.0 Hz, 1H), 3.64 – 3.59 (m, 1H), 3.43 (ddd, J = 
10.7, 10.7 and 3.4 Hz, 1H), 3.22 (m, 2H), 2.82 (dd, J = 12.1 and 2.1 Hz, 1H), 2.67 – 2.59 (m, 
2H), 2.42 (dd, J = 12.1 and 10.0 Hz, 1H); 
13
C NMR ((CD3)2SO, 125 MHz) δ 155.7, 151.9, 151.6, 
147.2, 145.9 (q, JCF = 6.3 Hz), 136.8, 124.8 (q, JCF = 270.9 Hz), 118.9, 117.1, 104.4 (q, JCF = 
30.0 Hz), 93.2, 73.6, 67.2, 48.9, 45.4, 44.9; LCMS (3.5 min) tR = 1.17 min; m/z (ESI
+
) 380 
(M+H
+
); HRMS m/z calcd for C16H17F3N7O (M + H) 380.1441, found 380.1438. 
2-Chloro-5-(trifluoromethyl)pyridin-4-amine (61). Et3N (2.80 mL, 20 mmol) was added to a 
solution of 2-chloro-5-(trifluoromethyl)isonicotinic acid (60; 1.5 g, 6.6 mmol) and diphenyl 
phosphorazidate (2.14 mL, 9.9 mmol) in 
t
BuOH (12 mL) and toluene (13.5 mL). The solution 
was stirred at 105°C for 5 h. The reaction mixture was cooled to rt and solvents were evaporated. 
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The residue was partitioned between water and EtOAc. The combined organic layers were 
washed with brine, dried, filtered and concentrated. Flash column chromatography, eluting with 
10% EtOAc–hexanes, gave tert-butyl (2-chloro-5-(trifluoromethyl)pyridin-4-yl)carbamate (1.24 
g, 4.2 mmol, 63%). 
1
H NMR (CDCl3, 500MHz) δ 8.50 (s, 1H), 8.45 (s, 1H), 7.00 (br s, 1H), 1.57 
(s, 9H); 
13
C NMR (CDCl3, 125 MHz) δ 156.3, 150.4, 146.8 (q, JCF = 7.1 Hz), 144.9, 123.0 (q, 
JCF = 275.8 Hz), 112.7, 111.5 (q, JCF = 31.2 Hz), 82.9, 27.6 (3C); LCMS (3.5 min) tR = 2.77 min; 
m/z (ESI+) 297 (M+H+); HRMS calcd for C11H13ClF3N2O2 (M + H) 297.0612, found 297.0627. 
CF3CO2H (6.44 mL, 84 mmol) was added to a solution of tert-butyl (2-chloro-5-
(trifluoromethyl)pyridin-4-yl)carbamate (1.24 g, 4.2 mmol) in CH2Cl2 (16.5 mL). The solution 
was stirred at rt for 5 h. Solvents were removed by evaporation and the residue was purified by 
ion exchange chromatography on SCX-II acidic resin, eluting with MeOH then 2M NH3 in 
MeOH. The basic fractions were combined to give 2-chloro-5-(trifluoromethyl)pyridin-4-amine 
(61; 0.736 g, 3.8 mmol, 90%). 
1
H NMR (CDCl3, 500MHz) δ 8.30 (s, 1H), 6.66 (s, 1H), 4.77 (br 
s, 2H); 
13
C NMR (CD3OD, 125 MHz) δ 154.0, 146.8 (q, JCF = 6.2 Hz), 124.2 (q, JCF = 268.0 
Hz), 108.9, 108.7 (q, JCF = 30.8 Hz), (one quaternary carbon not observed); LCMS (3.5 min) tR = 
1.82 min; m/z (ESI
+
) 197 (M+H
+
); HRMS m/z calcd for C6H5ClF3N2 (M + H) 197.0088, found 
197.0082.  
Biochemical assays. In vitro assays for inhibition of CHK1 and CHK2 were carried out as 
described previously.
18,19 
Cellular assays. Assays for the determination of checkpoint abrogation, antiproliferative 
activity, and potentiation of genotoxic drug efficacy in cancer cell lines were carried out as 
described previously.
19,21
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Crystallography. Crystallography of CHK1 kinase domain was carried out as described 
previously.
20
 Data were integrated with XDS
44
, imported with POINTLESS
S2
, then scaled and 
merged with AIMLESS
45
. Following molecular replacement as previously described, the 
structure was refined with COOT
46
 and BUSTER
47
. TLS parameters were generated with 
PHENIX
48
. Ligand geometry restraints were generated with GRADE
49
/MOGUL
50
. 
In vivo assays. All experiments using animals were performed in accordance with the local 
Animal Welfare and Ethical Review Board, the UK Home Office Animals Scientific Procedures 
Act 1986 and with the United Kingdom National Cancer Research Institute guidelines for the 
welfare of animals in cancer research.
51
 The ICR does not undertake research in non-rodent 
species and requires internal ethical review when such studies are sponsored by organizations 
with whom we collaborate. Collaborator-sponsored non-rodent pharmacology studies of 
compound 4 necessary for the prediction of therapeutic window were approved by the ICR 
Animal Welfare and Ethics Review Board and were conducted in full compliance with national 
regulations at AAALAC accredited R&D sites. Detailed experimental procedures are reported in 
the Supporting Information. 
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AMPK, 5'-AMP-activated protein kinase ATM; ataxia telangiectasia mutated; ATR, ataxia 
telangiectasia and Rad3-related; BINAP, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl); CDC25, 
cell division cycle 25; CHK1, checkpoint kinase 1; CHK2, checkpoint kinase 2; CDK1, cyclin 
dependent kinase 1; CLint, intrinsic clearance; DDR, DNA damage response; DELFIA, 
Dissociation-Enhanced Lanthanide Fluorescent Immunoassay; DNA, deoxyribonucleic acid; G1, 
Gap1 phase; G2, Gap 2 phase; GEMM, genetically engineered mouse model; HBD, hydrogen 
bond donors; hERG, human ether-a-go-go-related gene; KRAS, V-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog; MLM, mouse liver microsomes; MRI, magnetic resonance imaging; 
MTD, maximum tolerated dose; MYC, v-myc avian myelocytomatosis viral oncogene homolog; 
MYCN, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; N-Boc, 
N-tert-butyloxycarbonyl; NSCLC, non-small cell lung cancer; PBPK, physiological-based 
pharmacokinetic; PD, pharmacodynamic; PK, pharmacokinetic; RNA, ribonucleic acid; S, 
Synthesis phase; SRB, sulforhodamine B. 
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